Nuclear receptor binding SET domain protein 1 promotes epithelial-mesenchymal transition in paclitaxel-resistant breast cancer cells via regulating nuclear factor kappa B and F-box and leucine-rich repeat protein 11

References

• Qiong L, Yin J. Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9. Bioengineered. 2021 Dec;12(1):8822–8832.
   PubMed Web of Science ®Google Scholar
• Kolak A, Kamińska M, Sygit K, et al. Primary and secondary prevention of breast cancer. Ann Agric Environ Med. 2017 Dec 23;24(4):549–553.
   PubMed Web of Science ®Google Scholar
• Fahad Ullah M. Breast Cancer: current Perspectives on the Disease Status. Adv Exp Med Biol. 2019;1152:51–64.
   PubMed Web of Science ®Google Scholar
• Zong Y, Wu J, Shen K. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Oncotarget. 2017 Mar 7;8(10):17360–17372.
   PubMedGoogle Scholar
• Marupudi NI, Han JE, Li KW, et al. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007 Sep;6(5):609–621.
   PubMed Web of Science ®Google Scholar
• Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 2019;24:40.
   PubMed Web of Science ®Google Scholar
• Abu Samaan TM, Samec M, Liskova A, et al. Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer. Biomolecules 2019 Nov27;9(12):12.
   PubMed Web of Science ®Google Scholar
• Dan VM, Raveendran RS, Baby S. Resistance to Intervention: paclitaxel in Breast Cancer. Mini Rev Med Chem. 2021;21(10):1237–1268.
   PubMed Web of Science ®Google Scholar
• Tauchmann S, Almosailleakh M, Schwaller J. NSD1 in erythroid differentiation and leukemogenesis. Mol Cell Oncol. 2020 Sep 14;7(6):1809919.
   PubMed Web of Science ®Google Scholar
• Ettel M, Zhao L, Schechter S, et al. Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions. Pathology. 2019 Jun;51(4):392–398.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang F, Chen Q, et al. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway. J Exp Clin Cancer Res. 2019 Nov14;38(1):467.
   PubMed Web of Science ®Google Scholar
• Bui N, Huang JK, Bojorquez-Gomez A, et al. Disruption of NSD1 in Head and Neck Cancer Promotes Favorable Chemotherapeutic Responses Linked to Hypomethylation. Mol Cancer Ther. 2018 Jul;17(7):1585–1594.
   PubMed Web of Science ®Google Scholar
• Kawakami E, Tokunaga A, Ozawa M, et al. The histone demethylase Fbxl11/Kdm2a plays an essential role in embryonic development by repressing cell-cycle regulators. Mech Dev. 2015 Feb;135 31–42.
   PubMed Web of Science ®Google Scholar
• Liu X, Li J, Wang Z, et al. KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells. Front Oncol. 2021;11:653788.
   PubMed Web of Science ®Google Scholar
• Lu DH, Yang J, Gao LK, et al. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition. Oncol Rep. 2019 Feb;41(2):917–927.
   PubMed Web of Science ®Google Scholar
• Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001 Feb;107(3):241–246.
   PubMed Web of Science ®Google Scholar
• Lu T, Jackson MW, Wang B, et al. Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):46–51.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014 Mar;15(3):178–196.
   PubMed Web of Science ®Google Scholar
• Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014 Sep 23;7(344):re8.
   PubMed Web of Science ®Google Scholar
• Mittal V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018 Jan;24(13):395–412.
   Google Scholar
• Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018 Aug;12(4): 361–373.
   PubMed Web of Science ®Google Scholar
• Aktas B, Tewes M, Fehm T, et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11(4):R46.
   PubMed Web of Science ®Google Scholar
• Li S, Hao J, Hong Y, et al. Long Non-Coding RNA NEAT1 Promotes the Proliferation, Migration, and Metastasis of Human Breast-Cancer Cells by Inhibiting miR-146b-5p Expression. Cancer Manag Res. 2020;12:6091–6101.
   PubMed Web of Science ®Google Scholar
• Lin YC, Lee YC, Li LH, et al. Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. J Cell Sci. 2014 Jan 1;127(Pt 1):85–100.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu S, Zhu X, et al. LncRNA-encoded polypeptide ASRPS inhibits triple-negative breast cancer angiogenesis. J Exp Med. 2020 Mar 2;217(3):3.
   Web of Science ®Google Scholar
• Wu H, Gu J, Zhou D, et al. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ. J Cell Mol Med. 2020 Aug;24(15):8589–8602.
   PubMed Web of Science ®Google Scholar
• Qin S, Ning M, Liu Q, et al. Knockdown of long non-coding RNA CDKN2B-AS1 suppresses the progression of breast cancer by miR-122-5p/STK39 axis. Bioengineered. 2021 Dec;12(1):5125–5137.
   PubMed Web of Science ®Google Scholar
• Zang H, Li Y, Zhang X, et al. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p. Thorac Cancer. 2020 Jul;11(7):1891–1903.
   PubMed Web of Science ®Google Scholar
• Wang J, Yang K, Cao J, et al. Knockdown of circular RNA septin 9 inhibits the malignant progression of breast cancer by reducing the expression of solute carrier family 1 member 5 in a microRNA-149-5p-dependent manner. Bioengineered 2021 Nov;5.
   Web of Science ®Google Scholar
• Zhang J, Du YY, Lin YF, et al. The cell growth suppressor, mir-126, targets IRS-1. Biochem Biophys Res Commun. 2008 Dec 5;377(1):136–140.
   PubMed Web of Science ®Google Scholar
• Yang B, Wang F, Zheng G. Transmembrane protein TMEM119 facilitates the stemness of breast cancer cells by activating Wnt/β-catenin pathway. Bioengineered. 2021 Dec;12(1):4856–4867.
   PubMed Web of Science ®Google Scholar
• Gu ZL, Huang J, Zhen LL. Knockdown of otubain 2 inhibits liver cancer cell growth by suppressing NF-κB signaling. Kaohsiung J Med Sci. 2020 Jun;36(6):399–404.
   PubMed Web of Science ®Google Scholar
• Xue J, Chi Y, Chen Y, et al. MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. Oncogene. 2016 Jan 28;35(4):448–458.
   PubMed Web of Science ®Google Scholar
• Vaz SN, Santana DS, Netto EM, et al. Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection. Braz J Infect Dis. 2020 Sep-Oct;24(5):422–427.
   PubMed Web of Science ®Google Scholar
• Huang T, Tang L, Wang H, et al. Carbonic anhydrase 12 gene silencing reverses the sensitivity of paclitaxel in drug-resistant breast cancer cells. Bioengineered 2021 Oct;26.
   Web of Science ®Google Scholar
• Pan C, Izreig S, Yarbrough WG, et al. NSD1 mutations by HPV status in head and neck cancer: differences in survival and response to DNA-damaging agents. Cancers Head Neck. 2019;4(1):3.
   PubMedGoogle Scholar
• Qiao XJ, Gu Y, Du H, et al. Co-expression of CD24 and Hsp70 as a prognostic biomarker for lung cancer. Neoplasma. 2021 Sep;68(5):1023–1032.
   PubMed Web of Science ®Google Scholar
• Amin N, Nietlispach D, Qamar S, et al. NMR backbone resonance assignment and solution secondary structure determination of human NSD1 and NSD2. Biomol NMR Assign. 2016 Oct;10(2):315–320.
   PubMed Web of Science ®Google Scholar
• Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules 2016 Jul 22;21(7):7.
   Web of Science ®Google Scholar
• de Morais EF, Rolim LSA, de Melo Fernandes Almeida DR, et al. Biological role of epithelial-mesenchymal-transition-inducing transcription factors in head and neck squamous cell carcinoma: a systematic review. Arch Oral Biol. 2020 Nov;119:104904.
   PubMed Web of Science ®Google Scholar
• Ou R, Zhu L, Zhao L, et al. HPV16 E7-induced upregulation of KDM2A promotes cervical cancer progression by regulating miR-132-radixin pathway. J Cell Physiol. 2019 Mar;234(3):2659–2671.
   PubMed Web of Science ®Google Scholar
• Kong Y, Zou S, Yang F, et al. RUNX3-mediated up-regulation of miR-29b suppresses the proliferation and migration of gastric cancer cells by targeting KDM2A. Cancer Lett. 2016 Oct 10;381(1):138–148.
   PubMed Web of Science ®Google Scholar